<DOC>
	<DOCNO>NCT02927444</DOCNO>
	<brief_summary>This study assess immunogenicity safety booster vaccination NBP606 compare exist commercial vaccine , give concomitantly routine pediatric vaccination .</brief_summary>
	<brief_title>Immunogenicity Safety Study NBP606 Healthy Toddlers</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy infant complete 3 dos primary vaccination ( NBP606_PCVI_III_2013 ) , available followup study period . The LAR ( Legally Authorized Representative ) understand requirement study voluntarily consent participate study . Administration vaccine , except one provide study , within 1month prior booster study Known hypersensitivity component pneumococcal vaccine Any confirm suspected immunosuppressive immunodeficient condition Coagulation disorder contraindicate IM ( intramuscular ) vaccination Participation another study</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>15 Months</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>